Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zinzani, P.
Right arrow Articles by Baccarani, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zinzani, P.
Right arrow Articles by Baccarani, M
Haematologica, Vol 90, Issue 5, 702-703
Copyright © 2005 by Ferrata Storti Foundation

Clinical Trial, Phase II

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma

PL Zinzani, L Alinari, M Tani, M Fina, S Pileri, and M Baccarani

We assessed the impact of a reduced-dose (10 mg x 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. The overall response rate was 60% (2 complete responses and 4 partial responses). In terms of infectious toxicity, cytomegalovirus reactivation occurred in 1 (10%) patient.


This article has been cited by other articles:


Home page
 BloodHome page
H. C. Kluin-Nelemans, J. L. Coenen, J. E. Boers, G. W. van Imhoff, and S. Rosati
EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
Blood, August 15, 2008; 112(4): 1039 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. M. Horwitz
Novel Therapies and Role of Transplant in the Treatment of Peripheral T-Cell Lymphomas
Hematology, January 1, 2008; 2008(1): 289 - 296.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M. G. Bernengo, P. Quaglino, A. Comessatti, M. Ortoncelli, M. Novelli, F. Lisa, and M. T. Fierro
Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients
Haematologica, June 1, 2007; 92(6): 784 - 794.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.